GFAP and Alzheimer disease: Since plasma p-tau, Aβ42/Aβ40, and glial fibrillary acid protein (GFAP) results associate with Aβ PET [6, 8, 10, 48, 49], abnormal concentrations of these biomarkers are likely to be interpreted as high risk of developing AD in the future.